AzTrials
AzTrials

GastroparesisNCT06493032

The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM

A study testing Gastric Alimetry System in people with Gastroparesis, run by Indiana University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to investigate whether or not the investigators can utilize Body Surface Gastric Mapping to determine who would best benefit to receive G-POEM procedure and how Body Surface Gastric Mapping can be utilized with patients who have gastroparesis symptoms. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Gastroparesis
What is being tested?
Gastric Alimetry System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
7 Nov 2024to 1 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • Patients clinically eligible for G-Poem at our center.

Who cannot join

  • • Pregnant or breast-feeding
  • Patients with gastroparesis due to spinal cord injuries due to difficulties in conducting the BSGM. Of note, we rarely see gastroparesis in this context.
  • Inability to perform BSGM: history of severe skin allergies or sensitivity to cosmetics or lotions; chronically damaged or vulnerable epigastric skin (fragile skin, wounds, inflammation); patients unable to remain in a relaxed reclined position for the test duration.
  • Patients with abdominal drains or tubes

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jacqueline Peterman contact

317-278-9242

petermaj@iu.edu

Marita Salame, MD contact

masalame@iu.edu

United States1 site, 1 recruiting
  • Indiana University Health University Hospital

    Indianapolis, Indiana, 46202

    Jacque Peterman, 317-278-9242, petermaj@iu.edu

    Lainna Cohen, 317-278-0621, larcohen@iu.edu

    Recruiting

Other trials in United States

About this study

The purpose of this study is to investigate whether or not the investigators can utilize Body Surface Gastric Mapping to determine who would best benefit to receive G-POEM procedure and how Body Surface Gastric Mapping can be utilized with patients who have gastroparesis symptoms. the investigators may also be able to find more ways how Body Surface Gastric Mapping testing can benefit patients with gastroparesis and/or G-POEM procedure.

Read the detailed description

The aim of this protocol is to build on the investigators currently approved study to evaluate the outcomes and predictors of success of Gastric peroral endoscopic myotomy (G-POEM). The investigators plan to incorporate BSGM in determining the treatment success after G-POEM in patients with refractory gastroparesis and potentially identify a phenotype of gastroparesis patients who may respond more favorably to G-POEM based on their baseline BSGM profile. The currently approved G-POEM study (IRB #1708840627 and ClinicalTrials.gov ID NCT04434781) at our center tracks patients' symptoms and quality of life at baseline and post G-POEM. the investigators plan to supplement the existing study by adding BSGM variables. Although the investigators have specific outcomes identified, the investigators would like to stress that this is a pilot study that will serve to identify patterns and trends that could be studied further in the future using larger cohorts of patients.

The investigators' primary objective is to evaluate the safety and feasibility BSGM in refractory gastroparesis patients undergoing G-POEM.

the investigators will also investigate whether changes in BSGM measures correlate with changes in symptoms and quality of life.

Additionally, the investigators' aim to compare the diagnostic performance of BSGM, and gastric emptying scans as depicted on scintigraphy.

The investigators' primary aim is to assess the feasibility and safety of in gastroparesis patients undergoing G-POEM. Clinical success is defined as improvement in GCSI by 1 point or more compared to baseline.

The investigators will report four spectral metrics, each profiling distinct features of gastric function:

  • Body Surface Gastric Mapping Rhythm IndexTM (GA-RI) - a measure of gastric rhythm stability.
  • Principal Gastric Frequency - the frequency associated with stable, persistent gastric activity as defined by GA-RI.
  • BMI-adjusted amplitude.
  • Fed: Fasted Amplitude Ratio (ff-AR).

Although not directly related to this outcome, the investigators will continue our symptom analysis (as has been previously done under the existing G-POEM protocol) that includes both the pattern and severity of individual symptoms, such as vomiting, reflux, and belching. The investigators will continue to assess patient quality of life using standardized questionnaires (SF-36) at baseline and 3 months post-G-POEM as is currently done with the existing protocol.

This is an addition to an existing study protocol. The study will involve patients with refractory gastroparesis (proven on a 4-hour solid-phase gastric emptying scan, along with limited or no response (or intolerance) to at least 3 months of lifestyle adjustments, dietary modifications, and medications) who will undergo G-POEM. BSGM will be used to assess gastric motility before and after the procedure. This design allows for the collection of data at multiple time points to assess changes in BSGM phenotypes, gastroparesis symptoms, and other relevant variables over time.

The study team will enroll 20 participants who will undergo BSGM at baseline prior to G-POEM procedure and then again 3-6 months after G-POEM. The study team plan to contact participants prior to their standard of care clinic visit to ensure participants meet eligibility criteria. The study team will also explain the study over the phone using the telephone script that has been approved (Appendix 1). If they are interested in the study, the study team will schedule them for BSGM and go over prep instructions. Once the participant arrives in clinic, teh study team will consent in-person.

Conditions
Gastroparesis
Being tested
Gastric Alimetry System
Medical subject headings
Gastroparesis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gastric Alimetry SystemDevice

    Also called Body Surface Gastric Mapping, BSMG, Electrogastrography System

    medical device that uses a large sheet of electrodes to assess gastric motility

Study groups in NCT06493032
Study groupRoleWhat they receive
Body Surface Gastric MappingExperimentalNot described
Receives: Device: Gastric Alimetry System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body Surface Gastric Mapping Rhythm IndexTM (GA-RI)

    A measure of the concentration of amplitude in the gastric frequency band over time (between 0 and 1), which characterizes the rhythmic stability of the recorded gastric activity; also adjusted for BMI.

    Measured: Baseline, 3 months,6 months, up to 5 hours.

  2. Principal Gastric Frequency

    Characterizes the frequency associated with stable, persistent gastric activity as defined by GA-R

    Measured: Baseline, 3 months,6 months, up to 5 hours.

  3. BMI-Adjusted Amplitude (μV)

    characterizes the strength of the recorded gastric activity as an average of the whole-test amplitude, adjusted for BMI

    Measured: Baseline, 3 months,6 months, up to 5 hours.

  4. Fed: Fasted Amplitude Ratio (ff-AR)

    characterizes the responsiveness to a meal stimulus, which is calculated as a ratio of the maximal 1-h average postprandial amplitude to the amplitude in the preprandial period.

    Measured: Baseline, 3 months,6 months, up to 5 hours.

  5. SF-36

    a set of generic, coherent, and easily administered quality-of-life measures

    Measured: Baseline, 3 months,6 months, up to 5 hours.

Secondary outcomes (1)
  1. Body surface gastric mapping (BSMG)

    enables accurate cutaneous gastric bioelectrical recording and provides valuable insights into the pathophysiology of gastric dysmotility in addition to gastric emptying measurements

    Measured: Baseline, 3 months,6 months, up to 5 hours.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jul 2024
  2. Study start7 Nov 2024
  3. Primary completion1 Jun 2028 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
enrolling 20 participants who are being referred for G-POEM procedure into this study for a baseline alimetry and then again at 3-6 months.
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06493032
Sponsor's protocol ID
20972
Status last verified
Sep 2026
First submitted
24 May 2024
Last updated
8 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Gastric Alimetry System in people with Gastroparesis, run by Indiana University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jacqueline Peterman (317-278-9242, petermaj@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body Surface Gastric Mapping Rhythm IndexTM (GA-RI) (time frame: Baseline, 3 months,6 months, up to 5 hours.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in